IBM’s Make-or-Break Moment Arrives as Investors Seek Clarity After a Record Rout
Published on 07/22/2026 at 14:12 | Redaktion boerse-global.de
When IBM releases its full second-quarter results after the closing bell today, the stakes could hardly be higher. The stock is nursing wounds from a 25 percent single-day collapse on July 14 — the worst trading session in the company’s history — triggered by preliminary numbers that fell well short of expectations. At €185.72, the shares sit just 4 percent above their 52-week low of €178.52, a far cry from the June record of €292.85 that now looks like a distant memory.
The preliminary figures painted a grim picture. Revenue came in at $17.2 billion, up just 1 percent year-on-year and missing consensus estimates that had clustered around $17.86 billion to $17.9 billion. Adjusted earnings per share of $2.93 also fell short of the $3.01 to $3.02 analysts had penciled in. The infrastructure segment was the biggest drag, contracting 7 percent after posting 15 percent growth in the first quarter. Software managed only 5 percent growth, down from 11 percent in the prior period, while Red Hat expanded at a still-respectable 11 percent. The one bright spot was distributed infrastructure, which surged 37 percent.
CEO Arvind Krishna offered a blunt mea culpa, telling Reuters, “This quarter we faltered.” He attributed the weakness to a shift in corporate spending priorities: companies are pouring budgets into AI hardware — servers and storage chips — rather than IBM’s traditional software and mainframe offerings. The new z17 mainframe cycle started stronger than any predecessor, Krishna noted, but the subsequent pullback proved more severe than planned. Adding to the pressure, IBM is investing more than $10 billion in quantum computing through 2029, a long-term bet that does little to address near-term revenue gaps.
The Cashflow Squeeze and the Dividend Question
Today’s full report carries outsized importance because last week’s preliminary release was deliberately incomplete. IBM did not update its annual guidance, leaving the old targets in place: currency-adjusted revenue growth above 5 percent and a $1 billion year-on-year increase in free cash flow. To hit that cash flow goal of roughly $15.7 billion, the company needs to generate an additional $10.9 billion in the second half of 2026 — 10 percent more than it produced in the same period last year. So far, only $4.8 billion has come in during the first six months. The quarterly dividend of $1.69 per share, yielding about 3.2 percent, remains untouched for now, but any sign of strain on the payout would rattle income-focused investors.
Should investors sell immediately? Or is it worth buying IBM?
A Divided Analyst Camp
Wall Street is deeply split on what comes next. The average price target sits at $239.81, implying roughly 29 percent upside from current levels, but the range of opinions tells a more complicated story. Bank of America maintained its buy rating, arguing that IBM remains well-positioned for software growth beyond the current disruption. Dan Ives at Wedbush raised his target from $320 to $350, a notably bullish call. Morgan Stanley lifted its target to $293, and Oppenheimer went to $350.
On the other side, HSBC downgraded the stock to Reduce with a $191 target — barely above the current price and not intended as a recovery signal. UBS cut its 2026 revenue growth forecast from 5.5 percent to 3.6 percent, warning that the shift in client investment priorities could persist into the second half of 2026 and even into 2027. Rob Oliver at Baird initiated coverage with a Neutral rating and a $230 target, praising the hybrid-cloud AI strategy but expressing caution about software growth and the durability of the mainframe business. Stifel set its target at $235.
Technical Signals and an Overhang of Scrutiny
The stock’s relative strength index sits at 31.8, hovering near oversold territory but not yet flashing a definitive reversal signal. The shares trade well below both the 50-day moving average of €228.88 and the 200-day moving average of €234.46, leaving room for a technical bounce if sentiment improves. But the 30-day annualized volatility of 83.82 percent warns that sharp moves in either direction remain likely around today’s release.
Complicating matters, reports have emerged of an investigation into potential manipulation of IBM’s order pipeline, an issue that could weigh on management’s credibility regardless of the quarterly numbers. Insider buying over the past twelve months — three separate purchases — offers a counterpoint, though it has done little to stem the selloff.
What the Market Needs to Hear
The decisive question for today’s conference call is straightforward: will management confirm, raise, or cut its full-year guidance? And can Krishna provide concrete evidence that the delayed software deals are merely pushed into the third quarter rather than lost entirely? A guidance cut would validate fears that corporate budgets are undergoing a structural shift away from traditional software toward AI infrastructure. A reaffirmation backed by credible deal pipeline evidence could mark the beginning of a stabilization.
IBM at a turning point? This analysis reveals what investors need to know now.
The bull case rests on valuation and product momentum. IBM continues to expand its hybrid-cloud and AI portfolio, launching new managed Red Hat services, deepening its Google Cloud partnership, and rolling out the z17 and LinuxONE 5 platforms. The company also formed “Team ORION” for a defense partnership with the UK Ministry of Defence, launched the Lightwell AI security platform, and expanded its quantum computing collaboration with Singapore’s DIS and DSTA defense agencies. The modernization suite Bob received multi-agent functionality and the Bobalytics analytics tool. If the timing problem in client spending resolves, these building blocks could support a narrative of underlying strength.
The bear case warns that the problem runs deeper. UBS sees the spending shift extending into 2027. The price-to-earnings ratio has fallen near a five-year low, which could signal a value trap rather than a bargain. And the legal overhang adds a layer of uncertainty that no earnings beat can instantly erase.
With the stock at €185.72 and the 52-week low of €178.52 within striking distance, today’s report will determine whether IBM can defend that floor or whether a fresh leg lower awaits. The RSI near 32 offers no guarantee of protection if guidance disappoints. A reaffirmation with credible deal evidence, however, could spark a recovery rally toward the 50-day moving average at €228.88. The verdict arrives after the closing bell.
Ad
IBM Stock: New Analysis - 22 July
Fresh IBM information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
